| 27.09 16:11 | Sanofi und Regeneron erhalten US-Zulassung für Dupixent bei COPD |
| 27.09 15:52 | dpa-AFX: *REGENERON & SANOFI : DUPIXENT APPROVED IN U.S. FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT |
| 27.09 15:35 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD |
| 27.09 13:36 | dpa-AFX: Regeneron, Sanofi Say Dupixent Approved In China To Treat Chronic Obstructive Pulmonary Disease |
| 27.09 13:05 | dpa-AFX: *REGENERON PHARMA AND SANOFI: NMPA IN CHINA APPROVES DUPIXENT FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| 27.09 13:00 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD |
| 26.09 07:30 | dpa-AFX: GNW-Adhoc: Press Release: Availability of the Q3 2024 Aide mémoire |
| 23.09 09:01 | dpa-AFX: ANALYSE-FLASH: Barclays hebt Ziel für Sanofi auf 120 Euro - 'Overweight' |
| 23.09 09:01 | dpa-AFX: Barclays hebt Ziel für Sanofi auf 120 Euro - 'Overweight' |
| 23.09 06:42 | dpa-AFX: *BARCLAYS HEBT ZIEL FÜR SANOFI AUF 120 (105) EUR - 'OVERWEIGHT' |
| 23.09 06:42 | dpa-AFX: *BARCLAYS RAISES SANOFI PRICE TARGET TO 120 (105) EUR - 'OVERWEIGHT' |
| 21.09 00:36 | dpa-AFX: GNW-Adhoc: Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant |
| 20.09 14:54 | dpa-AFX: CHMP Recommends Expanded Approval Of Sanofi's Dupixent For Eosinophilic Esophagitis In Children |
| 20.09 14:30 | dpa-AFX: Sanofi Reports Positive Results From Phase 3 HERCULES Study Of Tolebrutinib In Multiple Sclerosis |
| 20.09 14:04 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Sanofi auf 'Neutral' - Ziel 100 Euro |
| 20.09 14:04 | dpa-AFX: JPMorgan belässt Sanofi auf 'Neutral' - Ziel 100 Euro |
| 20.09 14:02 | dpa-AFX: *SANOFI: DUPIXENT RECOMMENDED BY CHMP FOR EU APPROVAL TO TREAT EOSINOPHILIC ESOPHAGITIS IN KIDS |
| 20.09 13:45 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old |
| 20.09 11:30 | dpa-AFX: GNW-Adhoc: Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study |
| 17.09 08:15 | dpa-AFX: *CITIGROUP RAISES SANOFI PRICE TARGET TO 130 (125) EUR - 'BUY' |
|
|
